pellino E3 ubiquitin protein ligase 1Genealiases: []
Q-omics provides the consensus-scored PELI1 profile across patient tissues and cancer cell-line models. PELI1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, PELI1 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, PELI1 RNA expression shows 19,449 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRP, KIRC, and UVM as cancer lineages where PELI1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PELI1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PELI1 survival associations across molecular data types. PELI1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PELI1 RNA expression–survival associations across cancer types. High PELI1 expression shows unfavorable associations in KIRP, MESO and UVM, but favorable associations in KIRC, LUAD and SKCM. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for PELI1 RNA expression.
This table summarizes PELI1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for PELI1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PELI1 shows lower tumor expression in KICH and BRCA and higher tumor expression in KIRC, THCA, CHOL and LIHC. The KIRC box plot shows higher PELI1 RNA expression in tumor versus normal tissue (log2 FC = +0.611, t-test p < 0.001).
This table shows molecular features associated with PELI1 in patient tissues and cancer cell lines. In patient samples, PELI1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, PELI1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Lymphoma.
